Can academic structures improve access to CAR-T cells?

• Published in: Bulletin du cancer Vol. 111; no. 1; p. 62
• Main Authors: Le Guen, Camille, Grain, Audrey, Le Calvez, Baptiste, Saiagh, Soraya, Vrignaud, Florence, Eveillard, Marion, Clémenceau, Béatrice, Zahar, Mina Benjelloun
• Format: Journal Article
• Language: English; French
• Published: France 01.01.2024
• Subjects: Cell- and Tissue-Based Therapy; France; Genetic Vectors; Humans; Immunotherapy, Adoptive - methods; T-Lymphocytes; France; Développement; Innovation; Accessibility; Accessibilité; Development; Clinical trial; Thérapie génique ex vivo; Regulation; Essai clinique; Réglementation; Ex-vivo gene therapy
• ISSN: 1769-6917
• DOI: 10.1016/j.bulcan.2023.10.005

In France, hospital cell therapy units have not been authorised to routinely produce chimeric antigen receptor T lymphocytes (CAR-T cells), which would then be referred to as academic CAR-T cells. CAR-T cells are classified as advanced therapy medicinal products and correspond to genetically modified T lymphocytes ex vivo. The CAR-T cell production process is complex and requires scientific and technical expertise to meet the acceptance criteria of the pharmaceutical quality system. The most commonly used method for genetically modifying T lymphocytes is viral transduction (lentiviral or retroviral), which requires prior access to a batch of good manufacturing practice (GMP) grade viral vector. Because of its cost, this reagent is the main limiting factor for developing CAR-T cells. A CAR-T cell produced by an industrial company is expensive (around €350,000 per injection) and the time taken by the manufacturer to make it available to the clinician can vary from three to five weeks. By meeting the economic and ecological challenges, can academic structures improve access to CAR-T cells? In this article, we present the elements necessary for the feasibility of setting up CAR-T cell production in an academic structure.